share_log

HC Wainwright & Co. Reiterates Buy on Rani Therapeutics Hldgs, Maintains $20 Price Target

Benzinga ·  Sep 20, 2023 06:39

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Rani Therapeutics Hldgs (NASDAQ:RANI) with a Buy and maintains $20 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment